2018 Billing and Coding Guide for
|
|
- Ilene Phillips
- 6 years ago
- Views:
Transcription
1 Billing and Coding Guide for
2 Table of Contents 1. Introduction 2. Coding Quick Reference Guide 3. Coding for Probuphine (buprenorphine) implant National Drug Codes (NDC) 1 Healthcare Common Procedure Coding System (HCPCS) 2 International Classification of Diseases, Clinical Modification codes (ICD-10 CM) 3 Current Procedural Terminology (CPT ) code 4 4. Sites of Service Provider office, community based provider: CMS-1500 claim form 5 Hospital outpatient clinic: UB-04/CMS claim form 5. Braeburn Access Program Patient Enrollment Order Form 6. Important Safety Information for Probuphine 2
3 Introduction The general coding and billing information contained in this guide was compiled from public sources and is provided to help you understand the availability of reimbursement related to Probuphine (buprenorphine) implant. This guide is provided as general information only and is not intended as coverage or coding advice, nor is it intended to increase or maximize reimbursement by any payor. Braeburn cannot provide specific reimbursement rates, and does not guarantee any level of reimbursement. Braeburn makes no other representations or warranties regarding the selection of codes for procedures or compliance of the information in this guide with any other billing protocols or requirements. Similarly, all CPT, HCPCS and ICD-10-CM codes are supplied for information purposes only and represent no statement, promise or guarantee by Braeburn that these codes will be appropriate or that reimbursement will be made. As with all claims, individual hospitals and physicians are responsible for exercising independent clinical judgment in selecting the codes that most accurately reflect a patient s condition and the procedures performed. Laws, regulations, and policies concerning coding and payment are complex and subject to change. Physicians and hospitals should refer to current, complete, and authoritative publications, such as AMA CPT lists, Medicare transmittals, and third-party payor policies as the basis for selecting codes that describe care rendered to an individual patient, and may wish to contact individual Medicare contractors or other third-party insurers as needed. Probuphine (buprenorphine) implant for subdermal administration INDICATIONS AND USAGE PROBUPHINE contains buprenorphine, a partial opioid agonist. Probuphine is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphinecontaining product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet equivalent or generic equivalent). PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support. PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet equivalent or generic equivalent. Please see IMPORTANT SAFETY INFORMATION including BOXED WARNING on pages 14, 15 & 16 3
4 Coding Quick Guide Item Code Description HCPCS 1 Code J0570 Buprenorphine implant, 74.2 mg HCPCS Code G0516 Insertion of non-biodegradable drug delivery implants, 4 or more (services for subdermal rod implant) HCPCS Code HCPCS Code G0517 G0518 Removal of non-biodegradable drug delivery implants, 4 or more (services for subdermal implants) Removal with reinsertion, non-biodegradable drug delivery implants, 4 or more (services for subdermal implants) CPT 2 Code Insertion of single non-biodegradable implant CPT Code Removal of single non-biodegradable implant CPT Code CPT Code Removal and re-insertion of single nonbiodegradable implant Unlisted procedure, skin, mucous membrane and subcutaneous Potential ICD-10-CM 3 Codes F11.10 Opioid Abuse Uncomplicated F11.20 Opioid Dependence Uncomplicated F11.21 Opioid Dependence in Remission 11 Digit NDC Each Probuphine System Kit contains: 4 Probuphine non-biodegradable implantable rods (a subdermal implant containing 74.2 mg of buprenorphine which is the equivalent of 80 mg of buprenorphine hydrochloride); and one Probuphine Applicator 4
5 National Drug Codes: NDC The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. The NDC for Probuphine (buprenorphine) implant are: NDC Number Number Description 11 Digit NDC Number Each Probuphine System Kit contains: 4 Probuphine nonbiodegradable implantable rods (a subdermal implant containing 74.2 mg of buprenorphine which is the equivalent of 80 mg of buprenorphine hydrochloride); and one Probuphine Applicator CMS 1500 Claim Form 80 Character Abbreviated Descriptor: NDC Number Number Description 11 Digit NDC Number Each Probuphine Kit contains: 4 Probuphine nonbiodegradable implants rods and one Probuphine Applicator 5
6 Healthcare Common Procedure Coding System (HCPCS) 1 Codes The HCPCS Level II Code Set is one of the standard code sets used for medical claims processing of office administered drugs. The HCPCS is divided into two principal subsystems, referred to as level I and level II of the HCPCS. Level I of the HCPCS is comprised of CPT (Current Procedural Terminology), a numeric coding system maintained by the American Medical Association (AMA). The CPT is a uniform coding system consisting of descriptive terms and identifying codes that are used primarily to identify medical services and procedures furnished by physicians and other health care professionals. These health care professionals use the CPT to identify services and procedures for which they bill public or private health insurance programs. Decisions regarding the addition, deletion, or revision of CPT codes are made by the AMA. The CPT codes are republished and updated annually by the AMA. Level I of the HCPCS, the CPT codes, does not include codes needed to separately report medical items or services that are regularly billed by suppliers other than physicians. Level II of the HCPCS is a standardized coding system that is used primarily to identify products, supplies, and services not included in the CPT codes, such as ambulance services and durable medical equipment, prosthetics, orthotics, and supplies (DMEPOS) when used outside a physician's office. Because Medicare and other insurers cover a variety of services, supplies, and equipment that are not identified by CPT codes, the level II HCPCS codes were established for submitting claims for these items. The development and use of level II of the HCPCS began in the 1980's. Level II codes are also referred to as alpha-numeric codes because they consist of a single alphabetical letter followed by 4 numeric digits, while CPT codes are identified using 5 numeric digits. Level II HCPCS Codes for billing Probuphine HCPCS Code Description Use J0570 Buprenorphine implant, 74.2 mg Physician office and Outpatient Ambulatory Facilities Probuphine has been assigned a specific J-Code for Probuphine (J0570) beginning January 1, This for the drug code only. The Medicare Allowable is per implant (descriptor 74.2mg) and reimbursed at $ which is based on ASP. The 2017 ASP Drug Pricing Files can be found at the following link: McrPartBDrugAvgSalesPrice/2017ASPFiles.html. Please note that the content provided by the Center for Medicare and Medicaid Services is updated frequently and should be checked quarterly. Due to the variability of health plan design and reimbursement, the physician should contact the patient s payer provider relations representative prior to implanting Probuphine to determine reimbursement for the procedure 6
7 Potential Level I Current Procedural Terminology (CPT ) Administration Codes for billing Probuphine (buprenorphine) There are no current administration codes that describe the implantation or removal of Probuphine. Probuphine consists of 4 non-biodegradable implants. Providers should consult with their local carriers to identify the most appropriate administration coding procedures and required documentation. Type of Code Code Number Description HCPCS Code G0516 Insertion of non-biodegradable drug delivery implants, 4 or more (services for subdermal $ # rod implant) HCPCS Code G0517 Removal of non-biodegradable drug delivery implants, 4 or more (services for subdermal implants) $ # HCPCS Code G0518 Removal with reinsertion, non-biodegradable drug delivery implants, 4 or more (services for subdermal implants) $ # CPT Code Insertion of single non-biodegradable implant $ # CPT Code Removal of single non-biodegradable implant $ # The 2017 Medicare Physician Fee Schedule CPT Code Removal and re-insertion of single nonbiodegradable implant CPT Code unlisted procedure, skin, mucous membrane and subcutaneous $ # Payor Specific 7 The 2017 Medicare Physician Fee Schedule can be found at the following link: CPT Copyright 2014 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. The AMA assumes no liability for data contained or not contained herein. # Represents National amounts for the CMS Physician Fees when the service is provided in the physician s office (nonfacility setting) Due to the variability of health plan design and reimbursement, the physician should contact the patient s payer provider relations representative prior to implanting Probuphine to determine reimbursement for the procedure
8 International Classification of Diseases, 10 th Revision, Clinical Modification (ICD-10-CM) 6 Codes that may be appropriate for use when billing a claim for Probuphine (buprenorphine) The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is a system used by physicians and other healthcare providers to classify and code all diagnoses, symptoms and procedures recorded in conjunction with hospital care in the United States. ICD-10-CM is composed of codes with 3, 4, 5, 6 or 7 characters. Codes with three characters are included in ICD-10-CM as the heading of a category of codes that may be further subdivided by the use of fourth, fifth, sixth or seventh characters to provide greater specificity. A threecharacter code is to be used only if it is not further subdivided. While diagnosis coding to the correct level of specificity is the goal for all claims, for 12 months after ICD-10 implementation, if a valid ICD- 10 code from the right family (see question 5) is submitted, Medicare fee-forservice will process and not audit valid ICD-10 codes unless such codes fall in. 8
9 Potential ICD-10-CM Codes for use when billing a claim for Probuphine (buprenorphine) use most specific sub-coding possible ICD-10-CM Code F11 Opioid related disorders Code description F11.1 Opioid abuse F11.10 Opioid abuse uncomplicated F11.2 Opioid dependence F11.20 Opioid dependence uncomplicated F11.21 Opioid dependence in remission F11.24 F11.25 F11.29 Opioid dependence with opioid-induced mood disorder Opioid dependence with opioid-induced psychotic disorder Opioid dependence with other opioid-induced disorder with unspecified opioid-induced disorder F11.9 Opioid use, unspecified F11.90 Opioid use, unspecified uncomplicated F11.99 Opioid use, unspecified with unspecified opioidinduced disorder 9
10 2017 Physician Office Sample Claim Form: CMS , 6 Item 19 - When billing HCPCS J0570, some payers may ask providers to specify Probuphine (subdermal buprenorphine implant) with dosage administered and NDC , Kit or number of units, e.g. 4 Buprenorphine Implants 74.2mg NOTE: Some payers require alternate product codes (i.e., Medicaid claims). Please consult with your local payers or contact the Braeburn Access Program at for further information. Item 21 - Indicate diagnosis/diagnoses using appropriate ICD-10-CM codes, such as F11.10 (Opioid Abuse Uncomplicated), F11.20 (Opioid dependence, uncomplicated) or F11.21 (Opioid Dependence in Remission). Item 24D - Indicate appropriate HCPCS and CPT codes and modifiers if required. Be sure to enter either the procedure HCPCS codes of G0516-G0518 or the procedure CPT codes of or the unlisted CPT code (unlisted procedure, skin, mucous membrane and subcutaneous). NOTE: Individual payers will require documentation to adjudicate any claim billed with an unlisted CPT code. Please consult with your local payer or contact the Braeburn Access Program at for further information. Additional information on the procedure may be placed in Item 19. Item 24E - Refer to the diagnosis for this service (see box 21). Enter only one diagnosis pointer per line. Item 24G One Probuphine kit contains 4 subdermal implants (74.2 mg of Buprenorphine or 80 mg Buprenorphine HCL each). CMS has designated each Buprenorphine implant to represent 1 unit. For all payers, whether performed in the outpatient clinic or a physician s office, the entity should code for 4 units of J0570 unless otherwise directed by the payer. MLN/MLNMattersArticles/Downloads/MM9930.pdf 10
11 Sample CMS-1500 claim form (physician office billing) 11
12 2017 HOPD Sample Claim Form: UB-04/CMS ,6 Locator Box 42 Enter appropriate revenue code, such as: For Medicare, revenue code 0636 (drugs that require detailed coding) For non-medicare payers, revenue code 0250 (general pharmacy) Injection services may be reported with revenue code 0510 (clinic, general service) Locator Box 43 - Describe the implant procedure Locator Box 44 - indicate appropriate CPT and HCPCS codes and modifiers if required. The HCPCS codes G0516, G0517, or G0518 may be considered for documenting the procedural service. The following CPT codes may be considered for documenting the procedural service: 11981, 11982, or the unlisted CPT code (unlisted procedure, skin, mucous membrane and subcutaneous). Additional information on the procedure may be placed in Locator Box 80. Medicare and Private Payer claims will require HCPCS J0570 as of January 1, NOTE: Individual payers will require documentation to adjudicate any claim billed with an unlisted CPT code. Please consult with your local payer or The Braeburn Access Program at to confirm payer requirements. Locator Box 46 - Enter 1 unit for the kit of 4 Probuphine subdermal implants (296.8 mg of Buprenorphine or 320 mg Buprenorphine HCL). Locator Box 47 - indicate total charges. Locator Box 67 - Indicate diagnosis/diagnoses using appropriate ICD-10-CM codes, either F11.10 (Opioid Abuse Uncomplicated), F11.20 (Opioid dependence, uncomplicated) or F11.21 (Opioid Dependence in Remission). Locator Box 80 - When billing a not-otherwise-classified HCPCS code like J3490, some payers may ask providers to specify Probuphine (subdermal buprenorphine implant) with dosage administered and NDC
13 Sample UB-04 (CMS-1450) claim form (institutional billing) 13
14 Indication and Important Safety Information INDICATIONS AND USAGE PROBUPHINE contains buprenorphine, a partial opioid agonist. PROBUPHINE is indicated for the maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphinecontaining product (i.e., doses of no more than 8 mg per day of Subutex or Suboxone sublingual tablet equivalent or generic equivalent). PROBUPHINE should be used as part of a complete treatment program to include counseling and psychosocial support. PROBUPHINE is not appropriate for new entrants to treatment and patients who have not achieved and sustained prolonged clinical stability, while being maintained on buprenorphine 8 mg per day or less of a Subutex or Suboxone sublingual tablet or generic equivalent. WARNING: IMPLANT MIGRATION, PROTRUSION, EXPULSION and NERVE DAMAGE ASSOCIATED WITH INSERTION and REMOVAL Risk Associated with Insertion and Removal Insertion and removal of PROBUPHINE are associated with the risk of implant migration, protrusion, expulsion resulting from the procedure. Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion. Because of the risks associated with insertion and removal, PROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified, prior to performing insertions or prescribing PROBUPHINE implants. Patients must be monitored to ensure that PROBUPHINE is removed by a healthcare provider certified to perform insertions. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in PROBUPHINE (e.g., EVA). 14
15 WARNINGS AND PRECAUTIONS Serious Complications from Insertion and Removal: Rare but serious complications including nerve damage and migration resulting in embolism and death may result from improper insertion of drug implants inserted in the upper arm. Additional complications may include local migration, protrusion and expulsion. Incomplete insertions or infections may lead to protrusion or expulsion. All Healthcare Providers must successfully complete a live training program on the insertion and removal procedures and become certified in the PROBUPHINE REMS program, prior to performing insertions or prescribing PROBUPHINE implants. Addiction, Abuse and Misuse: Buprenorphine can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory and CNS Depression: Significant respiratory depression and death have occurred in association with buprenorphine particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other CNS depressants (including alcohol). Consider dose reduction of CNS depressants when used concomitantly. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Unintentional Pediatric Exposure: In the event an implant protrudes or comes out, keep the implant away from children. Buprenorphine can cause severe, possibly fatal, respiratory depression in children. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment is temporarily interrupted or discontinued, monitor patients for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to initiation and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patient is clinically stable on transmucosal buprenorphine and not dependent on full agonists before inserting PROBUPHINE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. Impairment of Ability to Drive and Operate Machinery: PROBUPHINE may impair the mental or physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery. 15
16 Other systemic effects: PROBUPHINE may cause orthostatic hypotension in ambulatory patients. Buprenorphine, may elevate cerebrospinal fluid pressure and should be used with caution in patients with head injury, intracranial lesions, and other circumstances when cerebrospinal pressure may be increased. Buprenorphine can produce miosis and changes in the level of consciousness that may interfere with patient evaluation. Buprenorphine has been shown to increase intracholedochal pressure, as do other opioids, and thus should be administered with caution to patients with dysfunction of the biliary tract. Infection at Implant Site: Infection may occur at the site of the insertion or removal. Excessive palpation may increase an opportunity for infection. Improper removal carries risk of implant-site infection. General Precautions: PROBUPHINE should be administered with caution in debilitated patients and those with myxedema or hypothyroidism; adrenal cortical insufficiency (e.g., Addison s disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; acute alcoholism; delirium tremens; or kyphoscoliosis. PROBUPHINE should also be administered with caution in patients with a history of keloid formation, connective tissue disease, e.g., scleroderma or history of recurrent MRSA infections. Most common side effects of PROBUPHINE include: headache, insomnia, rhinorrhea, upper respiratory tract infection, nausea, anxiety, back pain, depression, constipation, and vomiting. PLEASE SEE THE FULL PRESCRIBING INFORMATION, INCLUDING BOXED WARNING AND MEDICATION GUIDE, which you can access at To report SUSPECTED ADVERSE REACTIONS, contact Braeburn at or FDA at FDA-1088 or 16
17 Footnotes 1. NDC National Drug Code: The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated, compounded, or processed by it for commercial distribution. (See Section 510 of the Federal Food, Drug, and Cosmetic Act (Act) (21 U.S.C. 360)). Drug products are identified and reported using a unique, three-segment number, called the National Drug Code (NDC), which serves as a universal product identifier for drugs. FDA publishes the listed NDC numbers and the information submitted as part of the listing information in the NDC Directory which is updated daily. The information submitted as part of the listing process, the NDC number, and the NDC Directory are used in the implementation and enforcement of the Act. 2. HCPCS Level II Coding Process & Criteria: The Centers for Medicare and Medicaid (CMS) published on August 17, 2000 (45 CFR ) to implement the HIPAA requirement for standardized coding systems established the HCPCS level II codes as the standardized coding system for describing and identifying health care equipment and supplies in health care transactions that are not identified by the HCPCS level I, CPT codes. The HCPCS level II coding system was selected as the standardized coding system because of its wide acceptance among both public and private insurers. Public and private insurers were required to be in compliance with the August 2000 regulation by October 1, The HCPCS Level II Coding Process/Criteria document describes HCPCS level II coding procedures and coding criteria. 3. ICD-10-CM: The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) is a system used by physicians and other healthcare providers to classify and code all diagnoses, symptoms and procedures recorded in conjunction with hospital care in the United States. The Centers for Disease Control developed and maintains the ICD-10-CM code set. Learning-Network-MLN/MLNProducts/Downloads/ICD9-10CM-ICD10PCS-CPT-HCPCS-Code-Sets-Educational- Tool-ICN pdf 4. CPT, Current Procedural Terminology: The American Medical Association developed and maintains the official Current Procedural Terminology (CPT ) code set. Please refer to AMA website with any questions at the following link: The CPT is the most widely accepted medical nomenclature used to report medical procedures and services under public and private health insurance programs. CPT is maintained by the CPT Editorial Panel, which meets three times a year to discuss issues associated with new and emerging technologies as well as difficulties encountered with procedures and services and their relation to CPT codes. 5. CMS 1500 Form: The Form CMS-1500 is the standard paper claim form to bill Medicare Fee-For-Service (FFS) Contractors when a paper claim is allowed. In addition to billing Medicare. Form CMS-1500 may be suitable for billing various government and some private insurers. Education/Medicare-Learning-Network-MLN/MLNProducts/downloads/form_cms-1500_fact_sheet.pdf 6. Developed by Alchemy Healthcare Solutions LLC, 5/ UB-04 (CMS-1450) Form: The Form CMS-1450, also known as the UB-04, is the standard claim form to bill Medicare Administrative Contractors (MACs) when a paper claim is allowed. In addition to billing Medicare, the 837I and Form CMS may be suitable for billing various government and some private insurers. MLN/MLNProducts/Downloads/837I-FormCMS-1450-ICN pdf 17
2018 Billing and Coding Guide for
1 2018 Billing and Coding Guide for Table of Contents 1. Introduction 2. Coding Quick Reference Guide 3. Coding for Probuphine (buprenorphine) implant National Drug Codes (NDC) 1 Healthcare Common Procedure
More informationWelcome to the Braeburn Access Program for PROBUPHINE (buprenorphine) implant for subdermal
Welcome to the Braeburn Access Program for PROBUPHINE (buprenorphine) implant for subdermal administration CIII Dear Health Care Provider, Welcome to the Braeburn Access Program. As you are aware, Braeburn
More informationQuestions & Answers About Probuphine. Here are the answers to some questions you may have about the Probuphine implant:
Questions & Answers About Probuphine Here are the answers to some questions you may have about the Probuphine implant: 1. Can my doctor prescribe and insert Probuphine? 2. What should I do after the Probuphine
More informationProbuphine. (buprenorphine implant) New Product Slideshow
Probuphine (buprenorphine implant) New Product Slideshow Introduction Brand name: Probuphine Generic name: Buprenorphine Pharmacological class: Opioid (partial agonist-antagonist) Strength and Formulation:
More informationCorporate Medical Policy
Corporate Medical Policy Buprenorphine Implant for Treatment of Opioid Dependence File Name: Origination: Last CAP Review: Next CAP Review: Last Review: buprenorphine_implant_for_treatment_of_opioid_dependence
More informationBUPRENORPHINE. THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names
BUPRENORPHINE THERAPEUTICS Brands Suboxone (with naloxone) Probuphine (implant) see index for additional brand names Generic? Yes (not for with naloxone or implant) Class mu opioid receptor partial agonist
More informationNow available. A maintenance dose of SUBOXONE mg once daily is clinically effective for most patients*1. Once-daily dosing in a single tablet
Now available SUBOXONE Once-daily dosing1 12 mg and 16 mg tablets A maintenance dose of SUBOXONE 12-16 mg once daily is clinically effective for most patients*1 Effective maintenance dosing with SUBOXONE
More informationStrengthening our global leadership in treatment of addiction. Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018
Strengthening our global leadership in treatment of addiction Morgan Stanley Global Healthcare Conference September 13 th and 14 th 2018 Forward Looking Statements This presentation contains certain statements
More informationBUPRENORPHINE (PROBUPHINE & SUBLOCADE )
UnitedHealthcare Oxford Clinical Policy BUPRENORPHINE (PROBUPHINE & SUBLOCADE ) Policy Number: PHARMACY 291.6 T2 Effective Date: July 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Probuphine, Sublocade) Reference Number: CP.PHAR.289 Effective Date: 11.16.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the
More informationBUPRENORPHINE (PROBUPHINE & SUBLOCADE )
UnitedHealthcare Oxford Clinical Policy BUPRENORPHINE (PROBUPHINE & SUBLOCADE ) Policy Number: PHARMACY 291.5 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS
More information1-844-FAX-A360 ( )
1-844-ASK-A360 (1-844-275-2360) 1-844-FAX-A360 (1-844-329-2360) www.myaccess360.com For more information, call AstraZeneca Access 360 at 1-844-ASK-A360, Monday through Friday, 8 am to 8 pm ET. IMFINZI
More informationSUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets. Risk Evaluation and Mitigation Strategy (REMS) Program
SUBOXONE Film, SUBOXONE Tablets, and SUBUTEX Tablets Risk Evaluation and Mitigation Strategy (REMS) Program Office-Based Buprenorphine Therapy for Opioid Dependence: Important Information for Prescribers
More information2015 Facility and Physician Billing Guide Heart Valve Technologies
2015 Facility and Physician Billing Guide Heart Valve Technologies PHYSICIAN BILLING CODES Clinicians use Current Procedural Terminology (CPT 1 ) codes to bill for procedures and services. Each CPT code
More informationBilling & Coding Guide
Billing & Coding Guide CMS established a unique J-code to facilitate reimbursement of ENVARSUS XR J7503 Suggested Coding and Medicare Allowables Coding Overview and Payment Rates Used to Report Code Description
More informationSuboxone, Zubsolv, Bunavail (buprenorphine with naloxone sublingual tablets and film), Buprenorphine sublingual tablets
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.32 Subject: Suboxone Drug Class Page: 1 of 7 Last Review Date: June 24, 2016 Suboxone Drug Class Description
More information2015 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1
GE Healthcare 2015 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 April, 2015 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and
More informationWARNINGS AND PRECAUTIONS
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROBUPHINE safely and effectively. See full prescribing information for PROBUPHINE. PROBUPHINE (buprenorphine)
More informationCoding for the Contraceptive Implant and IUDs
LARC Quick Coding Guide 2018 UPDATE Coding for the Contraceptive Implant and IUDs CORRECT CODING can result in more appropriate compensation for services and devices. To help practices receive appropriate
More informationOpioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective
Opioid Stewardship and Managing the Opioid Crisis: A Health-Care Perspective February 13, 2018 Frank Vocci, PhD New Therapies on the Horizon The planners, editors, faculty and reviewers of this activity
More informationInspire Medical Systems. Physician Billing Guide
Inspire Medical Systems Physician Billing Guide 2019 Inspire Medical Systems Physician Billing Guide This Physician Billing Guide was developed to help providers correctly bill for Inspire Upper Airway
More informationSurgical Preparation Codes for Skin Replacement Surgery** Hospital Outpatient/Ambulatory Surgical Center Setting
2018 National Medicare Reimbursement Rate Summary* for Integra Dermal Regeneration Template, & Office Settings Integra LifeSciences Corporation compiles this summary of Medicare payment rates to provide
More informationPROBUPHINE is available only through a restricted program called the PROBUPHINE REMS Program. (5.2)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROBUPHINE safely and effectively. See full prescribing information for PROBUPHINE. PROBUPHINE (buprenorphine)
More information2018 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1
GE Healthcare 2018 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 May 2018 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and payment
More informationCPT Code Changes for 2013 Frequently Asked Questions Last Updated 12/2/2012
1. Why are CPT codes changing? CPT Code Changes for 2013 Frequently Asked Questions Last Updated 12/2/2012 CPT code changes occur every year. The Current Procedural Terminology, or CPT, code set is maintained
More information2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1
GE Healthcare 2017 Reimbursement Information for Mammography, CAD and Digital Breast Tomosynthesis 1 February 2017 www.gehealthcare.com/reimbursement This advisory addresses Medicare coding, coverage and
More informationProfessional CGM Reimbursement Guide
Professional CGM Reimbursement Guide 2015 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................
More informationTitan Pharmaceuticals Reports Positive Initial Results Of Probuphine Relaunch
January 31, 2019 Titan Pharmaceuticals Reports Positive Initial Results Of Probuphine Relaunch - Double-Digit Increase in Probuphine Shipments - SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 /PRNewswire/
More informationOpioid Step Policy. Description. Section: Prescription Drugs Effective Date: April 1, 2018
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Opioid Step Policy Page: 1 of 6 Last Review Date: March 16, 2018 Opioid Step Policy Description
More informationCODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT. Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE
CODING SHEETS CHRONIC INTRACTABLE PAIN MANAGEMENT Effective January 1, 2009 CODMAN 3000 NEUROMODULATION AND ONCOLOGY REIMBURSEMENT HOTLINE Phone: 800-609-1108 Email: codmanpump@aol.com Fax: 303-703-1572
More informationSANOFI PASTEUR INFLUENZA VACCINE PRESENTATIONS CODING AND BILLING CHECKLIST
SANOFI PASTEUR INFLUENZA VACCINE PRESENTATIONS 08-09 CODING AND BILLING CHECKLIST Are you ready? Are you sure that your systems are fully updated? Are you aware of important influenza vaccination payment
More information2 016 HF10 THERAPY HOSPITAL OUTPATIENT DEPARTMENT AND AMBULATORY SURGERY CENTER REIMBURSEMENT REFERENCE GUIDE
HF10 therapy, delivered by the Nevro Senza System, is a new high-frequency spinal cord stimulation technology designed to aid in the management of chronic intractable pain of the trunk/limbs, including
More information2016 Billing and Coding Reference. Stereotactic Treatment Delivery
2016 Billing and Coding Reference Stereotactic Treatment Delivery This CY 2016 billing and coding reference is intended to be a general resource for physicians and reimbursement professionals and is current
More informationUltrasound Reimbursement Information for Anesthesiology 1
GE Healthcare Ultrasound Reimbursement Information for Anesthesiology 1 January, 2009 www.gehealthcare.com/reimbursement This overview addresses coding, coverage, and for ultrasound guidance with continuous
More informationESSURE A RESOURCE FOR CODING
ESSURE REIMBURSEMENT GUIDE A RESOURCE FOR CODING INDICATION Essure is indicated for women who desire permanent birth control (female sterilization) by bilateral occlusion of fallopian tubes. IMPORTANT
More informationReimbursement Information for Diagnostic Musculoskeletal Ultrasound and Ultrasound-guided Procedures 1
GE Healthcare Reimbursement Information for Diagnostic Musculoskeletal Ultrasound and Ultrasound-guided Procedures 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage,
More informationReimbursement Information for Automated Breast Ultrasound Screening
GE Healthcare Reimbursement Information for Automated Breast Ultrasound Screening January 2015 www.gehealthcare.com/reimbursement The Invenia ABUS is indicated as an adjunct to mammography for breast cancer
More informationReimbursement specialists are available from 9 AM to 5 PM ET, Monday through Friday (excluding holidays) to assist you with:
Reimbursement specialists are available from 9 AM to 5 PM ET, Monday through Friday (excluding holidays) to assist you with: Disclaimer The billing and coding information contained in this document is
More informationTalking with your doctor
SUBOXONE (buprenorphine and naloxone) Sublingual Film (CIII) Talking with your doctor Opioid dependence can be treated. Talking with your healthcare team keeps them aware of your situation so they may
More informationUphold LITE Vaginal Support System 2015 Coding & Quick Reference Guide
Hospital Outpatient Coding Scenarios This guide contains specific information for two (2) common coding/reimbursement scenarios related to the use of the Uphold LITE Vaginal Support System when performed
More informationSAMPLE. Behavioral Health Services
Coding and Payment Guide www.optumcoding.com Behavioral Health Services An essential coding, billing, and reimbursement resource for psychiatrists, psychologists, and clinical social workers 2017 a ICD-10
More information2018 Cerebrovascular Reimbursement Coding Fact Sheet
The information contained in this document is provided for informational purposes only and represents no statement, promise, or guarantee by Cordis Corporation concerning levels of reimbursement, payment,
More informationFOR QUESTIONS PLEASE CONTACT US AT
MAGNETIC BONE- ANCHORED HEARING SYSTEM (BAHS) EFFECTIVE JANUARY 2018 Medtronic provides this information for your convenience only. It does not constitute legal advice or a recommendation regarding clinical
More informationInspire Medical Systems. Hospital Billing Guide
Inspire Medical Systems Hospital Billing Guide Inspire Medical Systems Hospital Billing Guide This Hospital Billing Guide was developed to help centers correctly bill for Inspire Upper Airway Stimulation
More informationReimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures Commonly Performed by Otolaryngologists
GE Healthcare Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures Commonly Performed by Otolaryngologists 1 January, 2013 www.gehealthcare.com/reimbursement imagination
More informationDraft Label HIGHLIGHTS OF PRESCRIBING INFORMATION INDICATIONS AND USAGE
1 2 3 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use PROBUPHINE safely and effectively. See full prescribing information for PROBUPHINE. PROBUPHINE
More informationCoronary intravascular ultrasound (IVUS)
2017 Coding and Medicare payment guide Coronary intravascular ultrasound (IVUS) All coding, coverage, billing and payment information provided herein by Philips Volcano is gathered from third-party sources
More informationINTRODUCING. Potential Monotherapy Option 5 Provided in Convenient Vials 1 Reimbursable J-Code Available 3
INTRODUCING The only FDA-approved morphine sulfate for intrathecal and epidural pain management for use in continuous microinfusion devices, packaged in convenient, easy-to-use vials. Available, Agreed-Upon
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Vivitrol (Extended-release injectable naltrexone) MP-072-MD-DE Provider Notice Date: 04/15/2018 Issue Date: 05/15/2018 Effective
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationProduct Name or Headline
Product Name or Headline Subhead goes here Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. The coding options listed
More informationReimbursement Guide. Hospital Outpatient. Please see Important Safety Information on page 2 and click here for full Prescribing Information.
Reimbursement Guide Hospital Outpatient Information provided in this resource is for informational purposes only and does not guarantee that codes will be appropriate or that coverage and reimbursement
More informationStrengthening our global leadership in treatment of addiction. Year-to-Date / Q Results November 1st
Strengthening our global leadership in treatment of addiction Year-to-Date / Q3 2018 Results November 1st Forward Looking Statements This presentation contains certain statements that are forward-looking
More informationReimbursement Information for Ultrasound-guided Procedures Performed by Anesthesiologists 1
GE Healthcare Information for Ultrasound-guided Procedures Performed by Anesthesiologists 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage, and payment for ultrasound
More informationDiagnostic and interventional venous procedures (lower extremity)
2017 Coding and Medicare payment guide Diagnostic and interventional venous procedures (lower extremity) All coding, coverage, billing and payment information provided herein by Philips Volcano is gathered
More informationReimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Vascular Procedures 1
GE Healthcare Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Vascular Procedures 1 January, 2013 www.gehealthcare.com/reimbursement This overview addresses coding, coverage,
More informationLumify. Lumify reimbursement guide {D DOCX / 1
Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing
More informationMedication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 Amended Date: 10/1/2015 DRAFT Table of Contents
Medication Assisted Treatment: Buprenorphine Clinical Coverage Policy 8A-3 10/1/2015 Table of Contents 1.0 Description of the Procedure, Product, or Service... 3 1.1 Definitions... 3 2.0 Eligibility Requirements...
More informationMen s Health Coding & Payment Quick Reference
Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements. The coding options listed within this guide are commonly used codes
More informationFractional Flow Reserve (FFR) and instant wave-free Ratio (The ifr modality)
2017 Coding and Medicare payment guide Fractional Flow Reserve (FFR) and instant wave-free Ratio (The ifr modality) All coding, coverage, billing and payment information provided herein by Philips Volcano
More informationL8618 TRANSMITTER CABLE FOR USE WITH COCHLEAR IMPLANT DEVICE OR AUDITORY OSSEOINTEGRATED DEVICE, REPLACEMENT Healthcare Common Procedure Coding System
L8618 TRANSMITTER CABLE FOR USE WITH COCHLEAR IMPLANT DEVICE OR AUDITORY OSSEOINTEGRATED DEVICE, REPLACEMENT Healthcare Common Procedure Coding System The Healthcare Common Procedure Coding System (HCPCS)
More informationReimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians
GE Healthcare Reimbursement Information for Diagnostic Ultrasound and Ultrasound-guided Procedures 1 Performed by Emergency Medicine Physicians January, 2013 www.gehealthcare.com/reimbursement This overview
More informationG0433 INFECTIOUS AGENT ANTIBODY DETECTION BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) TECHNIQUE, HIV-1 AND/OR HIV-2, SCREENING
G0433 INFECTIOUS AGENT ANTIBODY DETECTION BY ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) TECHNIQUE, HIV-1 AND/OR HIV-2, SCREENING Healthcare Common Procedure Coding System The Healthcare Common Procedure
More informationClinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.19 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationrecommended for patients with severe hepatic impairment (8.6) See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SUBUTEX (buprenorphine) sublingual tablet safely and effectively. See full prescribing information
More informationClinical Policy: Naltrexone (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Vivitrol) Reference Number: CP.PHAR.96 Effective Date: 03.01.12 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationCoding and Billing Guide for VARUBI Injectable Emulsion-IV and Tablets-Oral
Coding and Billing Guide for VARUBI Injectable Emulsion-IV and Tablets-Oral Please click here for full Prescribing Information and see Indication and Important Safety Information for VARUBI on page 3.
More informationProfessional CGM Reimbursement Guide
Professional CGM Reimbursement Guide 2017 TABLE OF CONTENTS Coding, Coverage and Payment...2 Coding and Billing...2 CPT Code 95250...3 CPT Code 95251...3 Incident to Billing for Physicians..............................................
More informationPharmacogenomic Testing for Warfarin Response (NCD 90.1)
Policy Number 90.1 Approved By UnitedHealthcare Medicare Reimbursement Policy Committee Current Approval Date 01/08/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable to UnitedHealthcare
More informationBehavioral Health Services An essential, coding, billing and reimbursement resource for psychiatrists, psychologists, and clinical social workers
CODING & PAYMENT GUIDE 2019 Behavioral Health Services An essential, coding, billing and reimbursement resource for psychiatrists, psychologists, and clinical social workers Power up your coding optum360coding.com
More informationFact Sheet. Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII
Zohydro ER (hydrocodone bitartrate) Extended-Release Capsules, CII Fact Sheet Zohydro ER (hydrocodone bitartrate) Extended-Release Capsule, CII, is a long-acting (extendedrelease) type of pain medication
More informationLinks in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Jurisdiction Oregon. Retirement Date N/A
Local Coverage Determination (LCD): MolDX: GeneSight Assay for Refractory Depression (L36324) Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website. Contractor
More informationClinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.
Clinical Policy: (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: 09.01.17 Last Review Date: 02.18 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationHealthcare Common Prodecure Coding System
G9458 PATIENT DOCUMENTED AS TOBACCO USER AND RECEIVED TOBACCO CESSATION INTERVENTION (MUST INCLUDE AT LEAST ONE OF THE FOLLOWING: ADVICE GIVEN TO QUIT SMOKING OR TOBACCO USE, COUNSELING ON THE BENEFITS
More informationPOWER TO HELP REVERSE AN OPIOID OVERDOSE
POWER TO HELP REVERSE AN OPIOID OVERDOSE FDA APPROVED Concentrated 4 mg dose Needle-free; no assembly required Designed for ease-of-use in the community setting Requires no specialized training* Not a
More informationLocal Coverage Article for Chiropractic Services (A47798) Contractor Information. Article Information. Contractor Name. Contractor Numbers
Local Coverage Article for Chiropractic Services (A47798) Print Contractor Information Contractor Name Novitas Solutions, Inc. Contractor Numbers 12501, 12502, 12101, 12102, 12201, 12202, 12301, 12302,
More informationNevro Reimbursement Support
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology operated at 10,000 Hz designed to aid in the management of chronic intractable pain of the trunk
More informationContractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC B. LCD ID Number: L34834 Status: A-Approved
LCD for Blood Glucose Monitoring in a Skilled Nursing Facility (SNF) (L34834) Contractor Name: Novitas Solutions, Inc. Contractor Number: 12502 Contractor Type: MAC B LCD ID Number: L34834 Status: A-Approved
More informationPRESCRIBING ALERT
www.empr.com PRESCRIBING ALERT Dear Healthcare Professional, At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring
More informationDsuvia (sufentanil) NEW PRODUCT SLIDESHOW
Dsuvia (sufentanil) NEW PRODUCT SLIDESHOW Introduction Brand name: Dsuvia Generic name: Sufentanil Pharmacological class: Opioid agonist Strength and Formulation: 30mcg; sublingual tabs (housed in a disposable,
More informationHF10 THERAPY 2018 Ambulatory Surgery Center Reimbursement and Coding Reference Guide
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology operated at 10,000 Hz designed to aid in the management of chronic intractable pain of the trunk
More informationWEBINAR 1 CODING FOR FLUZONE VACCINATION CODING AND BILLING FOR VACCINATION WITH FLUZONE, INFLUENZA VACCINES CRACKING THE CODES: UPDATED for
UPDATED for 2016-2017 CRACKING THE CODES: CODING AND BILLING FOR VACCINATION WITH FLUZONE, INFLUENZA VACCINES Value transfers to licensed health care professionals by pharmaceutical companies may need
More informationH F 1 0 T H E R A P Y R E I M B U R S E M E N T R E F E R E N C E G U I D E
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology designed to aid in the management of chronic intractable pain of the trunk/limbs without paresthesia.
More informationMEDICAL POLICY: Telehealth Services
POLICY: PG0142 ORIGINAL EFFECTIVE: 01/01/08 LAST REVIEW: 12/12/17 MEDICAL POLICY: Telehealth Services GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated
More informationThyrogen (thyrotropin alfa for injection) Billing and Coding Guide
thyrotropin alfa for injection Thyrogen (thyrotropin alfa for injection) Billing and Coding Guide For Physician s Offices and Hospitals The following is provided for informational purposes only and is
More informationFY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine
FY17 SCOPE OF WORK TEMPLATE Name of Program/Services: Medication-Assisted Treatment: Buprenorphine Procedure Code: Modification of 99212, 99213 and 99214: 99212 22 99213 22 99214 22 Definitions: Buprenorphine
More informationSUBOXONE (buprenorphine and naloxone) sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SUBOXONE safely and effectively. See full prescribing information for SUBOXONE. SUBOXONE (buprenorphine
More informationCounseling to Prevent Tobacco Use
News Flash Vaccination is the Best Protection Against the Flu. This year, the Centers for Disease Control and Prevention (CDC) is encouraging everyone 6 months of age and older to get vaccinated against
More informationCODING SHEET HYDROCEPHALUS REIMBURSEMENT. All Medicare information is current as of the time of printing.
CODING SHEET HYDROCEPHALUS REIMBURSEMENT All Medicare information is current as of the January 2014 Hydrocephalus ing Coding Options Commonly Billed Codes for Physicians, Hospitals, and Ambulatory Surgery
More information32 CFR (a)(4), (a)(6)(iii), and (a)(6)(iv)
CHAPTER 15 SECTION 1 ISSUE DATE: November 6, 2007 AUTHORITY: 32 CFR 199.14(a)(4), (a)(6)(iii), and (a)(6)(iv) I. APPLICABILITY This policy is mandatory for the reimbursement of services provided either
More informationClinical Policy: Buprenorphine-Naloxone (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX. Line of Business: Medicaid
Clinical Policy: (Suboxone, Bunavail, Zubsolv) Reference Number: CP.PMN.XX Effective Date: 09/17 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.19
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationFamily Planning Eligibility Program
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2
More informationKurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center
Kurt Haspert, MS, CRNP University of Maryland Baltimore Washington Medical Center Data from the National Vital Statistics System Mortality The age-adjusted rate of drug overdose deaths in the United States
More information2017 FlexHD Abdominal Wall Reconstruction Reimbursement Coding Reference
2017 FlexHD Abdominal Wall Reconstruction Reimbursement Coding Reference Most Commonly Reported ICD-10-CM Procedure Codes and Descriptors ICD-10-CM Description 0WUF0KZ Supplement Abdominal Wall with Nonautologous
More information2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE
2018 HEMODIALYSIS CATHETERS CODING AND REIMBURSEMENT GUIDE Contents Overview of Central Venous Access s for Hemodialysis 2 Procedures Using Hemodialysis s 2 Physician Reimbursement for Hemodialysis s 3
More informationSUBOXONE (buprenorphine and naloxone) sublingual film, for sublingual or buccal use CIII Initial U.S. Approval: 2002 RECENT MAJOR CHANGES
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SUBOXONE sublingual film safely and effectively. See full prescribing information for SUBOXONE sublingual
More informationBilling and Coding Information
Billing and Coding Information The information provided is for educational purposes only. The healthcare provider is fully responsible for billing and coding determinations. INDICATIONS Injectafer (ferric
More information